Fine chemical

Alvotech Announces Changes to its Leadership Team

Retrieved on: 
Thursday, December 1, 2022
University, FKA, Alvogen, Cancer, Teva Pharmaceuticals, Patient, Biosimilar, BS, Allergan, Respiratory disease, Partnership, Doctor of Philosophy, Actavis, Pharmacovigilance, DKSH, Teva, Physical pharmacy, CMO, Business administration, Woman, COVID-19, Stada Arzneimittel, Degenerative disease, Executive, Communication, Growth, Marketing, Osteoporosis, R, Management, Fine chemical, EU

Changes to the leadership team are effective January 1, 2023.

Key Points: 
  • Changes to the leadership team are effective January 1, 2023.
  • I am thrilled to welcome Hafrun, who is recognized for her strong leadership in the pharma business, to our team.
  • I am grateful to have been a part of the Alvotech story during an exciting time for the company, Mark Levick said.
  • I had the privilege of working with extremely committed and talented colleagues across the entire team, establishing Alvotech as a commercial company and improving patient access to biologic medicines.

MERGE’s Dr. Kirsten Ambegaokar Named To MM+M’s 40 Under 40 List Chicago

Retrieved on: 
Thursday, December 1, 2022
Biotechnology, Health, Pharmaceutical, Other Communications, Other Science, Research, Medical Devices, Marketing, Digital Marketing, Advertising, General Health, Communications, Health Insurance, Science, Aurora, Fox Chase Cancer Center, Happiness, Abbott, Bachelor of Arts in Applied Psychology, Adobe, Neuron, University, Health, GoodRx, Membrane protein, T-Mobile, Doctor of Philosophy, American Express, Boston Scientific, Blue Cross Blue Shield Association, Medical director, LG, Flow cytometry, Indiana University Health, Molecular biology, Marketing, GSK, Advocate Aurora Health, Multimedia, Engineering, Kate Spade, University of California, Los Angeles, Science, Organization, Fine chemical, Medicine, Fidelity, Oncology, Pomona College, Pharmacology, MERGE, Neuroscience

MERGE , a premium storytelling and technology company, is proud to announce that Kristen Henkins Ambegaokar, PhD, Medical Director, Life Sciences, has been named to MM+Ms fourth class of 40 Under 40 honorees.

Key Points: 
  • MERGE , a premium storytelling and technology company, is proud to announce that Kristen Henkins Ambegaokar, PhD, Medical Director, Life Sciences, has been named to MM+Ms fourth class of 40 Under 40 honorees.
  • (Photo: Business Wire)
    The 40 Under 40 list includes individuals who hail from a range of employers, from pharma and biotech companies and agencies to device manufacturers, analytics firms and health media.
  • Of course, that makes the 40 Under 40 selection process a challenge but its one that we embrace.
  • We are thrilled to have Kristen recognized by MM+M as a 40 under 40 honoree, says Pat McGloin, Chief Client Officer for MERGE.

Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference

Retrieved on: 
Thursday, December 1, 2022
FSHD, Fulcrum, Conference, Therapy, Fetal hemoglobin, Patient, Thalassemia, Hemoglobinopathy, Losmapimod, Facioscapulohumeral muscular dystrophy, Gene expression, Sickle cell disease, Fine chemical

CAMBRIDGE,Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m.

Key Points: 
  • CAMBRIDGE,Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a virtual fireside chat at the 2022 BofA Securities Biotech SMID Cap Conference, on Thursday, December 8, 2022 at 9:10 a.m.
  • ET
    A live audio webcast will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations .
  • Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need.
  • Fulcrums proprietary product engine, FulcrumSeek, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression.

Terns Pharmaceuticals to Present at the 2022 JMP Securities Hematology and Oncology Summit

Retrieved on: 
Thursday, December 1, 2022
BCR, CML, Acute leukemia, Fatty liver disease, Hematology, Annual report, NASH, BCR-ABL, Webcast, THR, Risk, Research, FXR, TKI, Obesity, Fine chemical, Pharmaceutical industry

This allosteric mechanism of action has already shown significant efficacy and tolerability improvements over second generation active-site TKIs.

Key Points: 
  • This allosteric mechanism of action has already shown significant efficacy and tolerability improvements over second generation active-site TKIs.
  • A live audio webcast of the presentation will be available on the investor relations page of the Terns Pharmaceuticals website at http://ir.ternspharma.com .
  • Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology, obesity and NASH.
  • Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

Everest Clinical Research, an Arlington Capital Partners Portfolio Company, Announces the Acquisition of Brightech International

Retrieved on: 
Thursday, December 1, 2022
Professional Services, Medical Devices, Health, Finance, Pharmaceutical, Biotechnology, Software, Growth, Organization, AGC Aerospace & Defense, Partner, Partnership, Biotechnology, Data management, Doctor of Philosophy, Workforce, Health, Family, Immunology, Arlington Capital Partners, Central nervous system, Biostatistics, Investment, Acquisition, Medical imaging, Fine chemical, Mount Everest, Oncology

Everest Clinical Research (Everest), a leading full-service contract research organization (CRO) with deep expertise in biostatistics and statistical programming, today announced it has acquired Brightech International (Brightech or the Company).

Key Points: 
  • Everest Clinical Research (Everest), a leading full-service contract research organization (CRO) with deep expertise in biostatistics and statistical programming, today announced it has acquired Brightech International (Brightech or the Company).
  • Founded in 2002, Brightech is a leading CRO that specializes in complex, value-add biostatistics, programming, and clinical data management services.
  • Malcolm Little, a Partner at Arlington Capital Partners, said, The highly complementary Brightech acquisition is a great start towards accelerating Everests inorganic growth.
  • Arlington Capital Partners is a Washington, DC-based private equity firm that has managed approximately $7 billion in capital commitments.

New England Biolabs® Introduces NEB Lyophilization Sciences™, Ltd.

Retrieved on: 
Thursday, December 1, 2022
Inc., FGL, RNA, Multimedia, Enzyme, PCR, Business operations, ENGLAND, OEM, Molecular biology, Therapy, NEB, Gene expression, Synthetic biology, Vaccine, Acquisition, Oil, Fine chemical, Medicine, New England Biolabs

IPSWICH, Mass., Dec. 1, 2022 /PRNewswire/ -- New England Biolabs (NEB®), a leading supplier of life science reagents, introduces New England Biolabs Lyophilization Sciences (NEB Lyo Sciences™) – a wholly owned subsidiary of NEB with expertise in the design, development and manufacturing of innovative solutions for ambient stored products.

Key Points: 
  • IPSWICH, Mass., Dec. 1, 2022 /PRNewswire/ -- New England Biolabs (NEB), a leading supplier of life science reagents, introduces New England Biolabs Lyophilization Sciences (NEB Lyo Sciences) a wholly owned subsidiary of NEB with expertise in the design, development and manufacturing of innovative solutions for ambient stored products.
  • In May 2021, NEB acquired Fluorogenics Limited (FGL), facilitating the combination of NEB's expertise in enzymology with FGL's extensive understanding of the lyophilization process.
  • NEB will continue to incorporate the capabilities of NEB Lyo Sciences into its existing OEM and Customized Solutions business, expanding the services that it offers.
  • NEW ENGLAND BIOLABSand NEBare registered trademarks of New England Biolabs, Inc.
    NEW ENGLAND BIOLABS LYOPHILIZATION SCIENCES, NEB LYO SCIENCES and LYOPRIME are trademarks of New England Biolabs, Inc.
    View original content to download multimedia: https://www.prnewswire.com/news-releases/new-england-biolabs-introduces-...

Israel Construction Industry Report Q4 2022: Sector Expecting 4.1% Annual Growth Through 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, Tier 3, Key, ILS, City, KPI-driven code analysis, Construction, Tier 2 capital, Commercial, Real estate, Cable television, Fine chemical, Maple syrup, Tier

The construction industry in Israel is expected to grow by 4.1% to reach ILS 1,12,043 million in 2022.

Key Points: 
  • The construction industry in Israel is expected to grow by 4.1% to reach ILS 1,12,043 million in 2022.
  • Despite near-term challenges in certain construction sectors, medium to long term growth story in Israel remains intact.
  • The construction industry in Israel is expected to grow steadily over the next four quarters.
  • Market Data and Insights: This report provides market size and forecast across 40+ construction segments for a period of 10 years from 2016-2025 in Israel.

Global Rapid Microbiology Tests Market Report to 2030 - Featuring Abbott Laboratories, Alere, Danaher and Orasure Technologies Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Medical Supplies, Health, Other Science, Clinical Trials, Research, Science, Growth, Population growth, Diagnosis, Microbiology, Food, Patient, Government, Infection, Water, Food industry, Investment, Fine chemical, Medical device, Oil, Marketing

Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global rapid microbiology tests market.

Key Points: 
  • Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global rapid microbiology tests market.
  • Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global rapid microbiology tests market.
  • This report concludes with company profiles section that highlights major information about the key players engaged in rapid microbiology tests market.
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Rapid Microbiology Tests market worldwide?

Global Contract Packaging Market Report 2022: A $104.58 Billion Market by 2027 - Industry Trends, Share, Size, Growth, Opportunities and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 1, 2022
Supply Chain Management, Professional Services, Packaging, Retail, Chemicals, Plastics, Manufacturing, Outsourcing Business, COVID-19, Research, R, POP, Printing, Food, Sterilization, RTE, F&B, Potash, Fine chemical, Growth

The "Contract Packaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Contract Packaging Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global contract packaging market size reached US$ 56.46 Billion in 2021.
  • Contract packaging, also known as co-packaging, assists businesses in hiring other companies to manage their packaging and supply chain requirements.
  • What has been the impact of COVID-19 on the global contract packaging market?

AmplifyBio Chooses Blue Mountain to Achieve GMP Compliance and Advance Digital Strategy

Retrieved on: 
Thursday, December 1, 2022
Toxicology, Quality, Title 21 CFR Part 11, Good manufacturing practice, CCMS, Calibration, GxP, Patient, Medical device, CFR, Maintenance, Gene therapy, Disease, GMP, Reliance Institute of Life Sciences, Software as a service, EAM, Cell, Mobile enterprise asset management, Computerized maintenance management system, CMMS, Safety, RAM, Fine chemical, Gemstone, Risk management, Biotechnology, Medication

STATE COLLEGE, Pa., Dec. 1, 2022 /PRNewswire/ -- AmplifyBio has selected Blue Mountain Regulatory Asset Manager (RAM) to help with incorporating industry best practices and ensuring electronic records compliance.

Key Points: 
  • STATE COLLEGE, Pa., Dec. 1, 2022 /PRNewswire/ -- AmplifyBio has selected Blue Mountain Regulatory Asset Manager (RAM) to help with incorporating industry best practices and ensuring electronic records compliance.
  • In one seamlessly integrated system, Blue Mountain RAM provides world-class calibration and maintenance management, all while ensuring GxP compliance.
  • To learn more about AmplifyBio, visit https://www.amplify-bio.com/
    About Blue Mountain Quality Resources:
    Leading the Life Sciences in GMP asset management for 30+ years, Blue Mountain offers deep Life Sciences domain expertise.
  • To learn more about Blue Mountain, visit: https://coolblue.com
    For more information, contact Akashi Perera at 814-234-2417 or [email protected].